[
  {
    "question": "History of no aura with a seizure on 2 ASM, EEG showed left temporal frontal spikes what is next",
    "option_a": "Video EEG",
    "option_b": "Intracranial EEG monitoring",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "When a patient with epilepsy fails two appropriate antiseizure medications (ASM) and has supportive EEG findings, it is considered drug\u2010resistant epilepsy. The next step in evaluation is often aimed at localizing the epileptogenic zone to assess for potential surgical candidacy. Video EEG monitoring is the non-invasive gold-standard method to capture and analyze ictal events in real\u2010time. Drug\u2010resistant epilepsy is typically due to a persistent or diffuse abnormal electrical activity in specific brain regions. In this case, left temporal\u2013frontal spikes on interictal EEG suggest an irritative zone in these regions. However, interictal recordings may not fully capture the dynamics of seizure onset and spread, which is why ictal recording is critical. A patient who experiences seizures without any aura may have rapid seizure propagation. The identification of spikes in the left temporal\u2013frontal area is an important lateralizing clue, yet noninvasive ictal recordings via video EEG are needed to confirm the focus. This aids in correlating the clinical semiology with electrophysiological data. After initial EEG findings, the differential diagnosis considers focal epilepsy versus secondary generalization. Differential conditions might include psychogenic non\u2010epileptic seizures (PNES) but these can usually be differentiated during captured events via video EEG. Additional imaging (MR, PET, SPECT) might also be considered if the noninvasive study remains inconclusive. First-line management involves optimizing seizure control with appropriate ASMs. When two or more medications fail, a comprehensive presurgical evaluation is indicated. The tiered approach is: 1) Prolonged non-invasive video EEG monitoring combined with high-resolution MRI and neuropsychological testing; 2) If localization remains ambiguous, then consider invasive intracranial EEG monitoring. In pregnancy and lactation, seizure management must be balanced against drug teratogenicity, so surgical options may be more strongly considered when medications are ineffective. Option A (Video EEG) is correct because it is the next non-invasive step used to capture a typical seizure and better localize the seizure onset zone. Option B (Intracranial EEG monitoring) is more invasive and is reserved for cases where non-invasive studies are non-diagnostic or when precise localization is still unclear after video EEG. 1) Failure of two adequate ASM trials defines drug-resistant epilepsy. 2) Ictal events captured by video EEG are critical for accurate localization before considering surgery. 3) Non-invasive methods should always precede invasive studies like intracranial EEG monitoring. Recent guidelines from the ILAE and epilepsy surgery societies emphasize the importance of video EEG in the presurgical evaluation of drug-resistant epilepsy. Advances in long-term monitoring and imaging have improved success rates in localizing seizure onset zones, which is crucial for surgical planning.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Patient on LEV for a long time what is possible side effect",
    "option_a": "Suicidal",
    "option_b": "Liver toxicity",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Levetiracetam (LEV) is a widely used antiseizure medication with a generally favorable side-effect profile. However, like many neurologically active medications, it may be associated with psychiatric side effects. Recognizing these is important for overall patient management. LEV binds to the synaptic vesicle protein SV2A, modulating neurotransmitter release. Although its precise mechanism of causing psychiatric side effects like suicidal ideation is not fully established, changes in neurotransmitter balance in limbic circuits are believed to play a role. Patients on long-term LEV may develop mood disturbances, irritability, or even suicidal thoughts. It is essential to monitor for behavioral changes, particularly in patients with a prior history of mood disorders or depression. When patients on LEV present with behavioral changes, clinicians should assess mood via validated screening tools and obtain a detailed psychiatric history. Differential diagnoses include depression secondary to chronic disease or other medication effects. First-line management involves periodic screening for depression or suicidal ideation, particularly with long-term LEV use. If significant psychiatric symptoms develop, consider dose reduction or switching to an alternative ASM. In pregnant or lactating women, LEV is considered one of the safer options, but mental health monitoring remains essential. Option A (Suicidal) is correct because post-marketing data and FDA warnings support that LEV may increase the risk for suicidal ideation. Option B (Liver toxicity) is incorrect as LEV is not typically associated with liver toxicity, unlike other ASMs such as valproate or carbamazepine. 1) Always monitor mood and behavioral changes in patients on LEV. 2) Suicidal ideation, although uncommon, is a serious potential side effect warranting prompt evaluation. 3) LEV is generally preferred during pregnancy, but vigilance about psychiatric side effects remains important. Recent studies and FDA advisories have reinforced the association between LEV and an increased risk of suicidal behavior. Ongoing research is exploring the neuropsychiatric profile of LEV to guide safer long-term use and appropriate risk stratification.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "The same scenario repeated this time with loss of awareness & sometimes TCS with normal interictal EEG & normal MRI",
    "option_a": "Video EEG",
    "option_b": "Interictal PET",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "In a patient with clinical seizures featuring loss of awareness and occasional tonic-clonic activity, a normal interictal EEG and MRI do not rule out epilepsy. Many patients have normal interictal studies because epileptiform activity may be transient, making ictal recording essential. Seizure discharges may be brief, and interictal periods may not exhibit any abnormalities. The fact that the MRI is normal supports the possibility of a non-lesional epilepsy or a subtle focus that is not easily detectable with routine imaging. A history of loss of awareness points toward focal onset impaired awareness seizures. Given that interictal recordings might miss abnormal activity in some patients, especially if seizures are infrequent or brief, prolonged monitoring is needed. The differential diagnosis includes other causes of transient loss of consciousness such as syncope or psychogenic non-epileptic seizures. Video EEG monitoring is the gold standard to differentiate these entities by providing simultaneous video and EEG data during an event. The first step in evaluation is prolonged video EEG monitoring to capture an ictal event and to determine the precise onset and propagation of seizure activity. If the video EEG is inconclusive, additional investigations like interictal PET or SPECT may be considered. Pregnancy and lactation considerations include choosing ASMs with better safety profiles in these populations and ensuring optimal seizure control while minimizing fetal exposure. Option A (Video EEG) is correct because capturing an actual seizure is the most reliable method to confirm the diagnosis and clarify the seizure type. Option B (Interictal PET) is less immediately useful in this non-lesional context and generally reserved for further evaluation in refractory cases where non-invasive studies have failed to precisely localize the focus. 1) A normal interictal EEG does not exclude epilepsy \u2014 ictal recordings are key. 2) Video EEG monitoring is crucial for distinguishing epileptic events from other causes of transient loss of consciousness. 3) In non-lesional epilepsy, additional functional imaging may be necessary if video EEG is insufficient. Recent guidelines underscore the importance of long-term video EEG monitoring in cases of suspected epilepsy with normal routine EEG and MRI. Advances in neurophysiological techniques have improved the detection rate of subtly localized epileptogenic zones.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Patients with epilepsy denied any aura with MRI picture of heterotopia what is the epilepsy classification",
    "option_a": "Unknown",
    "option_b": "Genetic",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Epilepsy",
    "explanation": "The ILAE classification of epilepsies distinguishes between genetic, structural, metabolic, immune, infectious, and unknown etiologies. MRI findings that reveal brain malformations, such as heterotopia, point toward a structural cause. Heterotopia represents a malformation of cortical development resulting from abnormal neuronal migration. This misplaced gray matter can serve as an epileptogenic focus even in the absence of clinical auras. Patients with heterotopia typically experience seizures due to the abnormal organization of cortical neurons. The absence of aura may occur because the epileptogenic process is related to the structural anomaly rather than a progressive spread of abnormal activity that triggers warning signs. When evaluating epilepsy, the presence of a structural lesion on MRI (such as heterotopia) helps differentiate structural epilepsies from those of genetic or unknown etiology. Differential diagnoses include cases where no lesion is seen (idiopathic or genetic epilepsy), but in this situation, the imaging is diagnostic. Management typically follows the general principles for focal epilepsy. First-line treatment involves antiseizure medications, and in cases where seizures are refractory, surgical evaluation may be considered. For women who are pregnant or lactating, the chosen ASM should have a favorable teratogenic profile, and surgical options, if indicated, must consider maternal\u2013fetal risk. Option A (Unknown) is incorrect because the MRI clearly shows a structural abnormality. Option B (Genetic) is not the best classification in this context since the abnormality is structural; while there can be genetic associations with heterotopia, the classification in modern epilepsy nosology is based on the presence of the lesion. Option C (assumed to represent Structural) is therefore correct. 1) Heterotopia is a classic example of a malformation of cortical development leading to epilepsy. 2) MRI evidence of a structural abnormality is key in classifying the epilepsy etiology under the ILAE system. 3) Even in the absence of aura, structural lesions can generate epileptogenic activity. Recent updates in epilepsy classification and surgical guidelines have emphasized the importance of neuroimaging findings. Studies continue to show that patients with cortical malformations like heterotopia are more likely to have drug-resistant epilepsy, guiding a more aggressive evaluation including presurgical assessment.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Which area if removed by surgery will result in seizure freedom:",
    "option_a": "Epileptogenic zone",
    "option_b": "Ictal onset zone",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "The epileptogenic zone is defined as the minimum area of cortex that must be resected to achieve seizure freedom. It integrates clinical, electrophysiological, and imaging data to identify the brain region responsible for seizure generation. Seizures result from abnormal synchronous neuronal discharges. The epileptogenic zone is the area where such abnormality is both necessary and sufficient to generate clinical seizures. Its boundaries may not exactly match areas of structural lesions or interictal discharges, demanding a multimodality approach to delineation. In patients with drug-resistant epilepsy undergoing evaluation for surgery, precise localization of the epileptogenic zone is essential. Surgical resection of this zone is most likely to result in long-term seizure control, which is why its accurate identification is a cornerstone of pre-surgical planning. Evaluation involves long-term video-EEG monitoring, high-resolution MRI, PET, SPECT, and sometimes invasive intracranial recordings. Differential zones include the ictal onset zone (where seizures begin) and the irritative zone (where interictal discharges originate), but only complete removal of the epileptogenic zone typically results in seizure freedom. First-line management for medically refractory epilepsy is a comprehensive surgical evaluation. Guidelines recommend a tiered approach: initial non-invasive evaluation (EEG, MRI, PET/SPECT) followed by invasive monitoring if necessary. In pregnant or lactating patients, risks must be balanced; minimizing exposure to anesthesia and ensuring seizure control is paramount, with multidisciplinary teams optimizing maternal and fetal outcomes. Option A (Epileptogenic zone) is correct because only removal of the tissue essential for seizure generation (the epileptogenic zone) is associated with seizure freedom. Option B (Ictal onset zone) reflects where seizures begin but may not encompass the entire network responsible for seizure propagation. 1. The epileptogenic zone is a theoretical construct determined through multimodal investigation. 2. Complete resection of the epileptogenic zone is crucial to achieving seizure freedom; partial resection may not suffice. Emerging techniques such as high-density EEG, magnetoencephalography (MEG), and advanced MRI protocols continue to refine the accuracy of epileptogenic zone localization, leading to improved surgical outcomes.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "The patient, an alcoholic with a known case of epilepsy on ASM came with active seizure, loaded with IV VPA. 2 days later was agitated and then decreased level of consciousness. Lab list all within normal",
    "option_a": "Send for ETOH level",
    "option_b": "Ammonia level",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "Valproic acid (VPA) is a commonly used anti-seizure medication. One recognized adverse effect of VPA is hyperammonemia, which may occur even when standard liver function tests remain normal. VPA can interfere with the urea cycle, leading to the accumulation of ammonia in the blood. The resultant hyperammonemia can impair neurological function, producing symptoms such as agitation and decreased level of consciousness. In this patient, who is a known epileptic and alcoholic, the presentation of agitation and altered consciousness two days post IV VPA loading (with normal labs) strongly suggests VPA-induced hyperammonemia. Alcohol use may also influence metabolism and enzyme function, complicating the picture. The workup for altered mental status in a patient on VPA should include serum ammonia measurement. Differential diagnoses include alcohol withdrawal, other metabolic derangements, or direct VPA toxicity with hepatic involvement; however, normal liver enzymes steer the focus toward hyperammonemia. The first step is to assess and confirm hyperammonemia by obtaining an ammonia level. Management may involve reducing or temporarily discontinuing VPA, and the use of L-carnitine has been supported to help reduce ammonia levels. In pregnant or lactating women, alternative medications with a better safety profile may be considered, and any intervention should involve careful risk-benefit analysis to protect both mother and baby. Option B (Ammonia level) is correct because it is the appropriate investigation for suspected VPA-induced hyperammonemia. Option A (Send for ETOH level) could be considered in alcohol-related issues, but the clinical scenario and normal laboratory evaluations point more toward a metabolic derangement from VPA. 1. Hyperammonemia can occur in patients on VPA even without abnormal liver function tests. 2. Always consider measuring ammonia levels in patients with altered mental status receiving VPA. Recent clinical guidelines support monitoring ammonia levels in patients on VPA who present with neurological changes. The beneficial role of L-carnitine supplementation in reducing ammonia levels has been increasingly recognized in recent studies.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Same scenario, EEG attached with interictal discharges asking about source zone:",
    "option_a": "Irritative Zone",
    "option_b": "Epileptogenic",
    "option_c": "Symptomatic",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "The irritative zone is the region of the brain from which interictal epileptiform discharges are generated. This zone, identified on EEG, often encompasses a larger area than the actual seizure onset or the epileptogenic zone. Interictal discharges occur as brief, abnormal neuronal firings during periods between seizures. The irritative zone represents the broader network of cerebral cortex that is predisposed to these abnormal discharges, although not all of this tissue may be essential for sustaining a seizure. In pre-surgical evaluation, identifying the irritative zone can help map out the extent of abnormal cortical activity. However, resecting only this zone may not always lead to seizure freedom if the critical epileptogenic tissue remains. EEG is the primary tool for delineating the irritative zone, as it demonstrates interictal spikes and sharp waves. Differential considerations include the ictal onset zone (where seizures commence during an event) and the epileptogenic zone (the minimal region necessary for seizure generation). While the irritative zone informs the mapping of epileptogenic networks, surgical planning targets the epileptogenic zone. A tiered approach using non-invasive EEG and imaging modalities is first utilized, followed by invasive monitoring when required. In pregnant or lactating patients, non-invasive evaluations are preferred, and management is carefully balanced to optimize maternal and fetal safety. Option A (Irritative Zone) is correct in the context of the question, which points to EEG findings of interictal discharges. Option B (Epileptogenic) would refer to the complete seizure-generating area, and Option C (Symptomatic) is not a standard term in this context. 1. The irritative zone may be more extensive than the actual epileptogenic focus. 2. Detailed correlation between EEG findings and clinical data is essential for accurate localization in epilepsy surgery. Advanced EEG techniques and neuroimaging continue to refine our understanding of the spatial distribution of interictal discharges. Recent literature underscores the importance of differentiating between the irritative and epileptogenic zones to improve surgical outcomes.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Short stature, long history of seizure, multiple skin macular and cutaneous tumors.",
    "option_a": "Tram track calcification",
    "option_b": "Multiple enhanced cortical tubers",
    "option_c": "Bilateral Optic Glioma",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "Tuberous sclerosis complex (TSC) is a genetic disorder classified among the neurocutaneous syndromes. It is characterized by the development of benign tumors (hamartomas) in the brain and other organs, as well as dermatological manifestations. Mutations in the TSC1 or TSC2 genes lead to dysregulation of the mTOR pathway, resulting in uncontrolled cell growth and the formation of cortical tubers, subependymal nodules, and other lesions. These cortical tubers are responsible for the high incidence of seizures in TSC. Patients with TSC typically present with a long history of seizures, cognitive impairment, and distinct skin findings such as ash leaf spots, shagreen patches, and facial angiofibromas. Short stature can also be a feature. The radiological finding of multiple enhanced cortical tubers aligns with the diagnosis. Diagnosis of TSC is based on clinical criteria supplemented by imaging findings. Brain MRI typically demonstrates multiple cortical tubers and subependymal nodules. Differential diagnoses include Sturge-Weber syndrome (characterized by tram-track calcifications) and neurofibromatosis type 1 (associated with optic gliomas). Treatment is multidisciplinary. First-line management involves anti-seizure medications for seizure control. mTOR inhibitors such as everolimus are used for treating certain manifestations like subependymal giant cell astrocytomas. Regular surveillance for renal, cardiac, and dermatologic involvement is indicated. In pregnant or lactating women, treatment requires careful selection of safe anti-seizure medications and monitoring for potential teratogenic effects, with a collaborative approach involving neurology, obstetrics, and genetics. Option B (Multiple enhanced cortical tubers) is correct as it directly describes the characteristic brain imaging finding in tuberous sclerosis. Option A (Tram track calcification) is typically seen in Sturge-Weber syndrome, while Option C (Bilateral Optic Glioma) is more common in neurofibromatosis type 1. 1. Tuberous sclerosis often presents with a triad of seizures, mental impairment, and facial angiofibromas. 2. Cortical tubers are a hallmark imaging finding that contributes to seizure generation in TSC. Recent advances in genetic testing and the use of mTOR inhibitors have significantly altered the management strategies for TSC. Updated consensus guidelines emphasize early diagnosis and a multidisciplinary approach for optimal management of neurological and systemic manifestations.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario with no aura but focal aware seizure presentation and uncontrolled in 2 ASM what is next",
    "option_a": "FDG-PET",
    "option_b": "Video EEG",
    "option_c": "SPECT",
    "option_d": "Repeat MRI with high resolution",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "In patients with focal seizures that remain uncontrolled despite trials of two appropriate antiseizure medications (a definition of drug\u2010resistant epilepsy), a detailed presurgical evaluation is warranted. The aim is to localize the epileptogenic zone so that targeted treatments (including surgery) can be considered. Focal aware (simple partial) seizures arise from a localized region of the cortex. When seizures become refractory despite two medication trials, it suggests that the underlying epileptogenic network is not adequately suppressed by medical therapy. Current evidence supports that identifying and precisely localizing the seizure onset zone is critical in drug\u2010resistant epilepsy. A patient who experiences focal aware seizures (without alteration of consciousness) that are uncontrolled by two antiseizure medications meets criteria for drug\u2010resistant epilepsy. This situation prompts advanced evaluation to determine if the patient is a candidate for surgical intervention. The initial step in presurgical evaluation is to record the clinical events under controlled conditions. Long-term video EEG monitoring (vEEG) is the standard to capture ictal events and localize the seizure focus reliably. Other imaging modalities (like high\u2010resolution MRI, FDG\u2010PET or SPECT) are used in conjunction with vEEG when structural or metabolic abnormalities are suspected, but capturing the seizures is essential. According to the 2017 ILAE and the 2022 American Epilepsy Society guidelines, the management of pharmacoresistant focal seizures requires comprehensive evaluation at an epilepsy center. First-line treatment remains ASMs tailored to seizure type and patient factors, but failure of two ASMs defines drug resistance. The next step is detailed presurgical evaluation including video-EEG monitoring to localize the epileptogenic zone. If a focal lesion is identified and concordant with EEG, surgical resection is considered first-line for cure. Other options include neuromodulation (VNS, RNS) if surgery is not feasible. The mechanism of video-EEG is to capture ictal events and define electroclinical correlation, guiding management decisions. Acute seizure management remains supportive, but long-term seizure control depends on identifying surgical candidates. Multidisciplinary care involving neurologists, neuropsychologists, and neurosurgeons is essential. Option A: FDG-PET \u2014 Incorrect as an immediate next step. FDG-PET is useful in MRI-negative epilepsy to identify hypometabolic regions but is adjunctive after video-EEG. It lacks temporal resolution and cannot replace ictal electroclinical correlation.  Option B: Video EEG \u2014 Correct. Video-EEG monitoring is the gold standard for capturing seizures with simultaneous clinical and EEG data, essential for localization in pharmacoresistant focal aware seizures. It guides surgical candidacy and further management.  Option C: SPECT \u2014 Incorrect as initial next step. Ictal SPECT requires seizure capture during injection, is logistically challenging, and is typically used after video-EEG or when MRI/PET are inconclusive.  Option D: Repeat MRI with high resolution \u2014 Incorrect as immediate next step. While repeat MRI can detect subtle lesions, without electroclinical data from video-EEG, its utility is limited. MRI should be done in parallel or after video-EEG findings suggest a focus. - **Pharmacoresistance is defined after failure of two appropriate ASMs.** - **Video-EEG is indispensable for seizure localization, especially in focal aware seizures without aura.** - **A normal MRI does not exclude a surgically remediable epilepsy; functional imaging and invasive monitoring may be needed.** - **Focal aware seizures may lack aura because the initial symptom is overt and objective.** - **Early referral to an epilepsy center improves outcomes in drug-resistant epilepsy.** - Memory aid: \"**Video-EEG first**\" \u2014 always capture seizures with EEG before advanced imaging. The 2017 ILAE definition of drug-resistant epilepsy states: \u201cDrug-resistant epilepsy is defined as failure of adequate trials of two tolerated, appropriately chosen and used antiseizure medication schedules to achieve sustained seizure freedom.\u201d (Kwan et al., Epilepsia 2010;58(4): 595-601).  The 2022 American Epilepsy Society guidelines emphasize: \u201cPatients with pharmacoresistant focal epilepsy should undergo prolonged video-EEG monitoring to capture seizures and define the epileptogenic zone before considering surgical or neuromodulatory treatments.\u201d (AES Guideline 2022).  Knowledge gaps remain in optimizing the sequence of advanced imaging modalities when video-EEG is inconclusive. Emerging techniques such as high-density EEG and magnetoencephalography (MEG) are promising but not yet standard. Multimodal approaches tailored to individual patients represent the evolving frontier in epilepsy diagnostics.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "child with typical scenario of benign rolandic epilepsy, what is the finding on EEG?",
    "option_a": "",
    "option_b": "correctly identifies the EEG finding of high",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "Benign rolandic epilepsy (also known as benign childhood epilepsy with centrotemporal spikes, BECTS) is a focal epilepsy syndrome typically seen in children between the ages of 3 and 13. It is characterized by focal motor seizures often affecting the face and oropharyngeal region, with seizures that commonly occur during sleep and a benign clinical course. The condition is believed to result from maturational immaturity in the perirolandic (centrotemporal) cortex. The abnormal cortical excitability produces characteristic high-voltage spikes in this region. Importantly, there is no underlying structural brain abnormality, distinguishing it from epilepsies due to identifiable lesions. Clinically, children with BECTS may present with seizures involving facial twitching, drooling, or altered speech, frequently occurring during sleep. Neurological examinations are typically normal, and cognitive outcomes remain favorable. The syndrome generally resolves by adolescence without long-term sequelae. The diagnosis is primarily established by a detailed clinical history and confirmed with an EEG. A sleep-deprived or sleep-recorded EEG will typically show high-voltage centrotemporal spikes that are often biphasic or triphasic, which are activated or accentuated by sleep. Differential diagnoses include other focal epilepsies (e.g., occipital lobe epilepsy) and generalized epilepsies like absence epilepsy, which have distinct EEG patterns. Management is often conservative given the benign nature of the syndrome. Many children may not require antiepileptic drugs unless seizures are frequent or disruptive. When treatment is indicated, options such as carbamazepine or levetiracetam may be used. In the context of pregnancy and lactation, if treatment is needed in a female patient with a history of BECTS or other epilepsies, selecting a drug with a favorable safety profile and minimal teratogenic risk is paramount. Preconception counseling and careful monitoring are recommended per current guidelines. Option B correctly identifies the EEG finding of high-voltage centrotemporal spikes, often referred to as rolandic spikes. Options describing generalized spike-and-wave discharges (seen in absence epilepsy), occipital spikes (seen in other focal epilepsies), or nonspecific EEG changes do not correspond with the hallmark EEG of BECTS. \u2022 A sleep EEG is often more sensitive in detecting centrotemporal spikes in BECTS.  \u2022 Despite frequent seizures, the prognosis remains excellent with spontaneous remission by adolescence.  \u2022 Treatment is not always necessary and should be tailored to seizure frequency and impact on functioning. Recent studies and clinical guidelines emphasize the role of EEG in confirming the diagnosis of BECTS based on the pattern of centrotemporal spikes. The overall management approach favors observation or minimal intervention due to the self-limited nature of the condition, and when treatment is needed, evidence supports using antiepileptic drugs with a benign side effect profile. In pregnancy and lactating patients with coexisting epilepsy, current guidelines recommend using the lowest effective dose of medications with favorable teratogenic profiles.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Case scenario typical of childhood absence epilepsy, has both absence and GTC, what ASM will worsen his seizures?",
    "option_a": "",
    "option_b": "",
    "option_c": ") is presumed to represent an agent such as carbamazepine. Carbamazepine is known to worsen absence seizures due to its sodium channel",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Epilepsy",
    "explanation": "Childhood absence epilepsy (CAE) is an idiopathic generalized epilepsy characterized by brief episodes of impaired consciousness due to typical 3-Hz spike\u2010and\u2010wave discharges on EEG. When a patient presents with both absence and generalized tonic-clonic (GTC) seizures, the antiepileptic medication (ASM) chosen must cover both seizure types. It is critical to avoid ASMs that can worsen any component of this mixed seizure syndrome. Absence seizures are linked to abnormal, hypersynchronous oscillations within the thalamocortical circuitry. Sodium channel blocking agents, by modifying neuronal excitability and perturbing thalamocortical network dynamics, can worsen these oscillations, thereby exacerbating absence seizures. Patients with CAE typically experience sudden, brief staring spells. When GTC seizures are also present, it indicates a broader involvement of generalized epileptic circuits. This duality makes treatment challenging, as some ASMs (like ethosuximide) are effective against pure absence seizures but not for GTC, whereas sodium channel blockers can actually worsen absence seizures. Diagnosis is based on clinical history and EEG findings (typically showing 3-Hz spike-and-wave complexes). Differential diagnoses include other idiopathic generalized epilepsies (e.g., juvenile myoclonic epilepsy), and care must be taken to differentiate from focal onset seizures which may also present with altered awareness. The treatment of CAE with mixed seizure types ideally involves an ASM that can address both absence and GTC seizures. Valproic acid is generally the first\u2010line choice. In contrast, ASMs like carbamazepine (a sodium channel blocker, as represented by option C) are avoided because they can exacerbate absence seizures. It is important to note that in women of childbearing age, valproate is typically avoided due to teratogenic risks, and alternative options (e.g., levetiracetam) might be considered, though they must be evaluated for efficacy in both seizure types, especially during pregnancy and lactation. In this MCQ, the marked answer (option C) is presumed to represent an agent such as carbamazepine. Carbamazepine is known to worsen absence seizures due to its sodium channel\u2013blocking properties. Other sodium channel blockers (e.g., phenytoin, oxcarbazepine) share this risk. Ethosuximide, while effective for absence seizures, is insufficient for GTC, and valproic acid is the optimal treatment if one is to control both seizure types. Therefore, using carbamazepine in such a patient is contraindicated and will worsen his seizures. \u2022 In patients with CAE and coexisting GTC seizures, avoid sodium channel blockers such as carbamazepine as they can exacerbate absence seizures.  \u2022 Ethosuximide is excellent for pure absence seizures but does not cover GTC events.  \u2022 Valproic acid is the broad-spectrum ASM of choice in mixed seizure presentations, but its teratogenicity necessitates caution in women of childbearing age. Current guidelines and studies continue to support the use of valproic acid in patients with mixed generalized seizures, while cautioning against the use of sodium channel blockers like carbamazepine in generalized epilepsy due to their potential to worsen absence seizures. Recent publications underscore the need to tailor therapy with consideration of both efficacy and safety, particularly with regard to special populations such as pregnant or lactating women.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "what is the most predictor of seizure recurrence if, patient known to have epilepsy and stopped his medications?",
    "option_a": "(presence of epileptiform abnormalities on EEG) is correctly identified as the strongest predictor of seizure recurrence after AED withdrawal. Other factors such as the duration of seizure freedom, seizure type, patient age, or the presence of a structural brain lesion, while relevant, are less predictive compared to the sensitivity of EEG abnormalities in detecting ongoing epileptogenicity. The option analysis correctly places EEG findings as the top predictor.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Epilepsy is characterized by recurrent, unprovoked seizures. One of the key predictors for seizure recurrence, especially after the withdrawal of antiseizure medications (AEDs), is the presence of epileptiform abnormalities on the electroencephalogram (EEG). These abnormalities indicate ongoing epileptogenic activity even in patients who are clinically seizure-free and thus serve as a sensitive biomarker when considering AED discontinuation. Interictal epileptiform discharges on EEG reflect abnormal neuronal excitability and hypersynchronous firing within the brain. These discharges indicate that the neural circuits remain unstable and capable of generating seizures despite a period of clinical remission. The persistence of these abnormalities suggests an underlying epileptogenic network that continues to predispose the patient to further seizures when AEDs are withdrawn. In clinical practice, many factors are considered when evaluating seizure recurrence risk, such as the duration of seizure freedom and the type of epilepsy. However, the presence of abnormal EEG findings is particularly telling. Even patients with prolonged periods without clinical seizures may have subclinical epileptiform discharges, which correlate with a higher likelihood of recurrence if medications are stopped. This underlines the importance of EEG monitoring in the decision-making process regarding AED withdrawal. The assessment involves obtaining serial EEG recordings to detect interictal epileptiform discharges. Although neuroimaging (such as MRI or CT scans) and clinical history (duration of seizure freedom, seizure type, age, presence of structural lesion) provide useful information, EEG findings remain the most potent predictor. In clinical practice, a normal EEG is often considered a favorable sign when contemplating AED withdrawal. Management of epilepsy, particularly decisions regarding AED withdrawal, requires a comprehensive evaluation of seizure control and underlying risk factors. According to the latest guidelines, persistent EEG abnormalities are a major contraindication to AED discontinuation. For women during pregnancy or lactation, careful management is paramount. Clinicians must balance the risks of seizure recurrence\u2014which could compromise maternal and fetal safety\u2014with the potential teratogenic effects of continuing AEDs. Tailoring treatment, possibly by using medications with the best safety profiles in pregnancy (such as lamotrigine, levetiracetam), and ensuring close monitoring is recommended if medication adjustments are needed. Option A (presence of epileptiform abnormalities on EEG) is correctly identified as the strongest predictor of seizure recurrence after AED withdrawal. Other factors such as the duration of seizure freedom, seizure type, patient age, or the presence of a structural brain lesion, while relevant, are less predictive compared to the sensitivity of EEG abnormalities in detecting ongoing epileptogenicity. The option analysis correctly places EEG findings as the top predictor. \u2022 An abnormal EEG in a seizure-free patient is a red flag indicating persistent epileptogenic activity.\n\u2022 Decisions to withdraw AEDs should ideally be based on a combination of a normal EEG and favorable clinical factors.\n\u2022 In women of reproductive age, particularly during pregnancy or lactation, the decision to modify AED therapy warrants additional caution to balance maternal seizure control and fetal/neonatal safety. Recent studies and clinical guidelines underline that the presence of interictal epileptiform discharges on EEG is a robust predictor of seizure recurrence after AED withdrawal. Evidence from prospective cohort studies has consistently shown that patients with abnormal EEGs have a significantly higher risk of relapse compared to those with normal EEG recordings. This solidifies the role of EEG in risk assessment and supports its use as a primary tool in guiding AED withdrawal decisions.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "patient known to have epilepsy for more than 10 years, said he has no aura, came to ED unwitnessed with tonic clonic seizures, what is the classification?",
    "option_a": "Unsknown onset, tonic clonic",
    "option_b": "Generalized onset tonic clonic",
    "option_c": "Focal to BTC",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Epileptic seizure classification is based on the seizure onset (focal, generalized, or unknown) and the evolution of clinical signs. When a seizure is unwitnessed, especially in a patient with established epilepsy, it is difficult to determine the precise onset, and the seizure is classified based on what is observed \u2013 in this case, the tonic-clonic phase. Epilepsy can arise from either a focal hyperexcitable area or from a more generalized abnormality affecting both hemispheres. In the absence of witness accounts, the initial focal or generalized onset is unclear. The lack of auras (subjective sensations signalling a focal onset) further undermines the ability to localize the onset, making it necessary to apply the 'unknown onset' classification. A patient with a 10-year history of epilepsy who experiences an unwitnessed tonic-clonic event and denies having an aura poses a diagnostic challenge. Although many patients with focal seizures may report auras, their absence does not rule out a focal seizure. Therefore, in the ED setting without witness information, clinicians are urged to describe the seizure based only on the observed convulsive stage. The diagnostic work-up includes a detailed history, collateral witness accounts if available, video-EEG monitoring, and neuroimaging. Differential diagnoses include focal seizures with secondary generalization versus primary generalized seizures. The acute description of the convulsive phase is insufficient to clearly assign focal onset unless further evidence is provided. In the ED setting for an unwitnessed tonic-clonic seizure, the management focuses on ensuring patient safety, airway protection, and stabilization. Subsequent investigations (EEG, MRI) help refine the classification. In patients with known epilepsy, the antiepileptic drug regimen may need revisiting. Pregnancy and lactation considerations require using medications with established safety profiles \u2013 for example, avoiding valproate in women of childbearing potential due to teratogenicity and considering alternatives such as levetiracetam or lamotrigine. Option A ('Unknown onset, tonic clonic') is correct because the lack of witnessed information about the seizure onset precludes a clear distinction between a primary generalized tonic-clonic seizure versus a focal-to-bilateral tonic-clonic seizure. Option B suggests a generalized onset, and Option C implies a focal onset with secondary generalization; both require aura or other lateralizing features that are not available here. 1. An unwitnessed seizure should be classified as 'unknown onset' until additional data is available. 2. The absence of an aura does not reliably exclude a focal onset. 3. Detailed history and collateral information are critical in seizure classification. Recent guidelines from the ILAE emphasize the importance of descriptive classification in cases where the seizure onset is not witnessed. Emerging research supports the use of prolonged video-EEG monitoring to reduce uncertainty in seizure onset classification.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "palpitation and sweating, localization of seizure?",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "Localization of seizures is attempted by correlating clinical manifestations with the region of the brain involved. However, autonomic symptoms such as palpitations and sweating are considered non\u2010specific and can be seen in seizures originating from various areas. Autonomic symptoms can occur due to involvement of structures that regulate the autonomic nervous system, including the insular cortex, temporal lobe, and sometimes frontal lobe. This variability makes it difficult to pinpoint a single anatomical region solely based on these symptoms. A patient presenting with palpitations and sweating during a seizure might initially suggest temporal lobe involvement since the limbic system is often implicated. However, because similar symptoms may arise from other regions, the clinical presentation does not allow definitive localization. Diagnosis and localization require a comprehensive evaluation including a detailed semiological description, EEG studies, and neuroimaging. Differential considerations include temporal lobe epilepsy, insular seizures, and other focal epilepsies. However, autonomic signs alone have limited localization value. Management involves conducting further investigations such as video-EEG and MRI to more precisely localize the seizure focus if possible. In acute settings, symptomatic treatment is provided. For women of childbearing potential, clinicians must choose antiepileptics that are safer during pregnancy and lactation, such as levetiracetam or lamotrigine, avoiding agents like valproate when possible. The marked answer B is considered correct if it represents the option 'Unknown' as the localization. Specific options that mention the temporal lobe, frontal lobe, or insular cortex, while having some association with autonomic manifestations, are overly specific given the nonspecific nature of the findings. Thus, labeling the localization as 'Unknown' is the best choice. 1. Autonomic symptoms such as palpitations and sweating are non-specific for the localization of a seizure. 2. A definitive localization typically requires a constellation of signs along with EEG and imaging correlation. 3. Always correlate autonomic symptoms with other clinical features for accurate localization. Current research underlines that while temporal lobe epilepsy is often associated with autonomic symptoms, there is significant overlap with other regions. Updated guidelines recommend a multimodal diagnostic approach, including video-EEG monitoring and advanced imaging techniques, to improve localization accuracy.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "case scenario of JME, what is characteristic feature?",
    "option_a": ", which identifies 'myoclonic jerks shortly after awakening' as the characteristic feature, is correct. Other options that might suggest the presence of focal seizures, seizures exclusively at night, normal EEG, or structural abnormalities are inconsistent with the known features of JME.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Juvenile Myoclonic Epilepsy (JME) is classified as an idiopathic generalized epilepsy syndrome. Its characteristic feature is the presence of myoclonic jerks, typically occurring shortly after awakening. JME is believed to have a genetic component leading to neuronal hyperexcitability. The pathogenesis involves widespread cortical involvement with a predilection for the areas that regulate motor control, hence the typical myoclonic jerks. These jerks frequently occur in the morning, which corresponds with the wake\u2010up period. Clinically, patients with JME exhibit myoclonic jerks that are often most prominent shortly after waking. They may also experience generalized tonic-clonic seizures and less frequently absence seizures. This morning predominance of symptoms helps differentiate JME from other epilepsy syndromes. EEG is the key diagnostic tool, typically demonstrating generalized polyspike and slow wave discharges. Differential diagnoses include focal epilepsies with myoclonic elements and other generalized epilepsy syndromes that present with different semiology. First-line therapy for JME is sodium valproate; however, due to its teratogenicity, it is avoided in women of childbearing potential. Alternatives such as levetiracetam or lamotrigine are preferred in pregnant or lactating patients. Long-term management involves lifestyle modifications such as maintaining regular sleep patterns and avoiding triggers like flickering lights. Option A, which identifies 'myoclonic jerks shortly after awakening' as the characteristic feature, is correct. Other options that might suggest the presence of focal seizures, seizures exclusively at night, normal EEG, or structural abnormalities are inconsistent with the known features of JME. 1. Myoclonic jerks shortly after awakening are a hallmark of JME. 2. Generalized polyspike-wave discharges on EEG are typically seen in JME. 3. Medication choices must consider reproductive potential due to the teratogenic risks of some antiepileptics. Recent studies continue to support the diagnostic criteria for JME based on clinical and EEG findings. Guidelines now emphasize careful drug selection, especially in women of childbearing potential, with a growing trend towards the use of levetiracetam and lamotrigine over valproate.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "early myoclonic encephalopathy with migrating myoclonuc then became more generalized, EEG finding?",
    "option_a": "",
    "option_b": "is correct as it describes the classic EEG finding in EME: a suppression",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "Early myoclonic encephalopathy (EME) is a neonatal epileptic encephalopathy characterized by severe seizures and a distinct pattern on EEG. The hallmark is a suppression-burst pattern with migrating epileptiform discharges. EME results from severe metabolic or genetic disturbances in the neonatal period, leading to diffuse brain dysfunction. The migrating multifocal epileptiform discharges against a background of suppression-burst reflect diffuse cortical irritability and an unstable neurophysiological state. Infants with EME typically present with myoclonic jerks that are multifocal and appear to migrate from one region of the body to another, eventually becoming more generalized. This clinical presentation, coupled with the distinct EEG findings, aids in differentiating EME from other neonatal epileptic syndromes. The diagnosis is primarily based on EEG findings, which show a suppression-burst pattern with migrating discharges. Differential diagnoses include Ohtahara syndrome (which also shows suppression-burst but may not have migrating discharges) and West syndrome (characterized by hypsarrhythmia). Comprehensive metabolic and genetic workups are also crucial. Management of EME is challenging. First-line treatment focuses on addressing underlying metabolic disorders when present and using anticonvulsant medications such as pyridoxine, benzodiazepines, or other agents tailored to neonatal physiology. As these patients are neonates, treatment strategies must account for the delicate balance of efficacy and potential adverse effects. Although pregnancy and lactation are less directly relevant, maternal medications may need adjustments if breastfeeding is considered, and neonatal drug exposure must be minimized. Option B is correct as it describes the classic EEG finding in EME: a suppression-burst pattern with multifocal, migrating epileptiform discharges. Other options suggesting continuous generalized spike-wave discharges, focal epileptiform discharges without migration, or hypsarrhythmia correlate with other epileptic encephalopathies and thus are incorrect. 1. EME is characterized by a suppression-burst pattern with migrating epileptiform discharges on EEG. 2. Early recognition is crucial given the severity and refractory nature of neonatal epileptic encephalopathies. 3. A thorough metabolic and genetic evaluation is important in the management of EME. Recent research has focused on the genetic and metabolic underpinnings of EME, as well as refining EEG criteria for early diagnosis. Guidelines emphasize early intervention, although response to therapy remains variable. New insights from genomic studies are beginning to inform more targeted interventions.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Young female who is known to have epilepsy wants to start OCP, which is correct response?",
    "option_a": "Increase lamotrigine to 2 folds",
    "option_b": "Increase lamotrigine to 4 folds",
    "option_c": "(the marked answer) is presumed to represent the strategy of monitoring the patient and adjusting the dose only if breakthrough seizures or subtherapeutic lamotrigine levels are documented. Option D is not provided. Thus, option C is correct as it endorses an individualized, monitored approach.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Epilepsy",
    "explanation": "Lamotrigine is an antiepileptic drug whose plasma levels can be significantly altered by drug\u2013drug interactions. Estrogen\u2010containing oral contraceptive pills (OCPs) accelerate the metabolism of lamotrigine via induction of uridine-diphosphate glucuronosyltransferase (UGT) enzymes, potentially lowering its serum concentration. Estrogen in combined OCPs increases the glucuronidation of lamotrigine, often reducing its blood level by approximately 50%. This pharmacokinetic interaction may reduce seizure control if the drug concentration falls below the therapeutic threshold. Importantly, the magnitude of this reduction varies between individuals, and when the OCP is stopped, lamotrigine levels may rebound, risking toxicity if the dose isn\u2019t readjusted appropriately. A young woman with epilepsy on lamotrigine who starts an estrogen-containing OCP may be at risk for breakthrough seizures due to lower lamotrigine levels. However, many patients remain stable despite the drop. The key is clinical vigilance\u2014monitoring for any change in seizure frequency and, if necessary, checking serum lamotrigine levels to guide dose adjustments. The assessment involves careful clinical monitoring and, if indicated, periodic measurement of serum lamotrigine levels. Differential considerations for breakthrough seizures include compliance issues, other drug interactions, or progression of the epileptic disorder. Therefore, rather than automatically doubling the dose, therapy should be individualized. Current guidelines recommend that physicians do not preemptively increase lamotrigine dose merely because an OCP is initiated. Instead, the approach is to counsel the patient on the possibility of reduced drug levels and to monitor for any signs of breakthrough seizures. If seizure control worsens or serum levels drop significantly, a gradual dose increase (often around a two\u2010fold increase) may be warranted. In pregnant patients or those in the postpartum period where hormonal fluctuations are significant, close monitoring is essential. Many experts now advocate for individualized dosage adjustment based on clinical response and serum levels rather than routine automatic dose escalation. Option A (Increase lamotrigine 2\u2010fold) and Option B (Increase lamotrigine 4\u2010fold) suggest preemptive, fixed-dose increases, which may unnecessarily expose the patient to side effects or toxicity if not clinically indicated. Option C (the marked answer) is presumed to represent the strategy of monitoring the patient and adjusting the dose only if breakthrough seizures or subtherapeutic lamotrigine levels are documented. Option D is not provided. Thus, option C is correct as it endorses an individualized, monitored approach. \u2022 Estrogen-containing OCPs can reduce lamotrigine levels by approximately 50%. \u2022 Always individualize dose adjustments based on clinical observation and serum level monitoring. \u2022 When discontinuing an OCP, be cautious of a potential rebound increase in lamotrigine levels. Recent studies highlight the variability of the lamotrigine-OCP interaction and discourage a routine automatic doubling of the lamotrigine dose. Instead, expert consensus and updated guidelines recommend close clinical observation with serum drug-level monitoring to tailor dose adjustments according to each patient\u2019s response.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "laryngeal spasm, what is the localization of seizure?",
    "option_a": "(Increase lamotrigine 2\u2010fold) and Option B (Increase lamotrigine 4\u2010fold) suggest preemptive, fixed",
    "option_b": "",
    "option_c": "(the marked answer) is presumed to represent the strategy of monitoring the patient and adjusting the dose only if breakthrough seizures or subtherapeutic lamotrigine levels are documented. Option D is not provided. Thus, option C is correct as it endorses an individualized, monitored approach.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Epilepsy",
    "explanation": "Lamotrigine is an antiepileptic drug whose plasma levels can be significantly altered by drug\u2013drug interactions. Estrogen\u2010containing oral contraceptive pills (OCPs) accelerate the metabolism of lamotrigine via induction of uridine-diphosphate glucuronosyltransferase (UGT) enzymes, potentially lowering its serum concentration. Estrogen in combined OCPs increases the glucuronidation of lamotrigine, often reducing its blood level by approximately 50%. This pharmacokinetic interaction may reduce seizure control if the drug concentration falls below the therapeutic threshold. Importantly, the magnitude of this reduction varies between individuals, and when the OCP is stopped, lamotrigine levels may rebound, risking toxicity if the dose isn\u2019t readjusted appropriately. A young woman with epilepsy on lamotrigine who starts an estrogen-containing OCP may be at risk for breakthrough seizures due to lower lamotrigine levels. However, many patients remain stable despite the drop. The key is clinical vigilance\u2014monitoring for any change in seizure frequency and, if necessary, checking serum lamotrigine levels to guide dose adjustments. The assessment involves careful clinical monitoring and, if indicated, periodic measurement of serum lamotrigine levels. Differential considerations for breakthrough seizures include compliance issues, other drug interactions, or progression of the epileptic disorder. Therefore, rather than automatically doubling the dose, therapy should be individualized. Current guidelines recommend that physicians do not preemptively increase lamotrigine dose merely because an OCP is initiated. Instead, the approach is to counsel the patient on the possibility of reduced drug levels and to monitor for any signs of breakthrough seizures. If seizure control worsens or serum levels drop significantly, a gradual dose increase (often around a two\u2010fold increase) may be warranted. In pregnant patients or those in the postpartum period where hormonal fluctuations are significant, close monitoring is essential. Many experts now advocate for individualized dosage adjustment based on clinical response and serum levels rather than routine automatic dose escalation. Option A (Increase lamotrigine 2\u2010fold) and Option B (Increase lamotrigine 4\u2010fold) suggest preemptive, fixed-dose increases, which may unnecessarily expose the patient to side effects or toxicity if not clinically indicated. Option C (the marked answer) is presumed to represent the strategy of monitoring the patient and adjusting the dose only if breakthrough seizures or subtherapeutic lamotrigine levels are documented. Option D is not provided. Thus, option C is correct as it endorses an individualized, monitored approach. \u2022 Estrogen-containing OCPs can reduce lamotrigine levels by approximately 50%. \u2022 Always individualize dose adjustments based on clinical observation and serum level monitoring. \u2022 When discontinuing an OCP, be cautious of a potential rebound increase in lamotrigine levels. Recent studies highlight the variability of the lamotrigine-OCP interaction and discourage a routine automatic doubling of the lamotrigine dose. Instead, expert consensus and updated guidelines recommend close clinical observation with serum drug-level monitoring to tailor dose adjustments according to each patient\u2019s response.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "TLE with auditory features typical case asking genetic mutation?",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "Temporal Lobe Epilepsy (TLE) can present with simple partial seizures that include auditory auras. There is a specific familial syndrome\u2014autosomal dominant partial epilepsy with auditory features (ADPEAF)\u2014that has been linked in some studies to LGI1 mutations. However, typical sporadic TLE with auditory features does not have a single, pathognomonic genetic mutation. This distinction is key, as the familial lateral temporal epilepsy with auditory manifestations is a distinct clinical entity. In TLE, aberrant electrical discharges originate in temporal lobe structures. In mesial TLE, the hippocampus and adjacent mesial structures are involved, whereas lateral TLE (which may present with auditory auras) involves the lateral temporal cortex. While certain genetic mutations like LGI1 have been implicated in familial cases (ADPEAF), the common sporadic form of TLE is considered to have a multifactorial basis without a single definitive genetic mutation. Patients with TLE may experience auditory auras (such as hearing buzzing or music) before progressing to impaired awareness seizures. Although LGI1 mutations have been described in autosomal dominant lateral temporal lobe epilepsy with auditory features, these cases have distinct clinical and electrographic patterns compared to the more common sporadic TLE. Thus, routine genetic testing is not indicated in typical TLE presentations. Diagnosis is primarily clinical, supplemented with EEG and high-resolution MRI to evaluate for mesial temporal sclerosis or other structural anomalies. In cases where a hereditary epilepsy syndrome is suspected, such as ADPEAF with a clear family history, genetic testing (including for LGI1) can be considered. However, in the absence of a familial pattern, no single gene mutation reliably explains typical TLE with auditory features. Management of TLE centers on antiepileptic drugs (AEDs); agents such as carbamazepine, lamotrigine, or levetiracetam are commonly used. In pregnancy, medications with lower teratogenic profiles like lamotrigine and levetiracetam are preferred. Breastfeeding considerations also favor these agents due to their safety profiles. Treatment is tailored to seizure control and minimizing side effects, rather than targeting a specific genetic defect. The options mentioning SCN1A (associated with Dravet syndrome), LGI1 (linked to ADPEAF, a distinct clinical entity), and DEPDC5 (associated with familial focal epilepsies with variable phenotypes) do not apply to the typical TLE with auditory features seen in most patients. Hence, the correct answer is that no single genetic mutation is definitively associated with the typical form of TLE with auditory features \u2013 effectively, 'None' is correct (option B). While auditory auras are a hallmark of lateral temporal lobe involvement, it is important to distinguish between familial syndromes (which may warrant genetic testing) and sporadic TLE, where a multifactorial etiology is more common. A careful family history is essential for determining if a genetic workup is appropriate. Recent research highlights the polygenic and multifactorial nature of TLE. Although LGI1 mutations are found in a well-defined familial epilepsy syndrome, most cases of TLE with auditory features do not have an identified single genetic mutation. Current guidelines emphasize clinical evaluation, EEG, and MRI as the mainstay of diagnosis and management, with genetic testing reserved for atypical or familial cases.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "developemental delay, multiple seizure types (tonic spasm, drop attacks,) finding in EEG?",
    "option_a": ", which identifies hypsarrhythmia on EEG, is the correct choice as it directly correlates with the pathognomonic findings in West syndrome. Options B (generalized spike",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "West syndrome is an epileptic encephalopathy that typically presents in infancy with a triad: infantile spasms (which may be tonic spasms and drop attacks), developmental delay, and a chaotic EEG pattern known as hypsarrhythmia. This EEG pattern is characterized by high-amplitude, disorganized, multifocal spike-and-wave discharges. The underlying pathophysiology involves abnormalities in brain development, whether due to genetic defects, structural brain anomalies, or metabolic disturbances. These lead to disorganized neuronal firing and the characteristic hypsarrhythmia seen on EEG, reflecting widespread cortical dysregulation. Clinically, children with West syndrome present with clusters of spasms and marked developmental delays. The presence of both tonic spasms and drop attacks correlates with the severe epileptic activity, and the classic EEG finding of hypsarrhythmia confirms the diagnosis. Diagnosis is based on the clinical triad combined with the EEG evidence of hypsarrhythmia. Differential diagnoses include absence epilepsy (which shows generalized spike-wave discharges), focal epilepsies (with localized epileptiform discharges), and Lennox-Gastaut syndrome (characterized by a slow spike-and-wave pattern). The clinical picture in West syndrome is distinguished by its early onset, the specific type of spasms, and the chaotic EEG pattern. First-line treatment of West syndrome includes hormonal therapy such as high-dose adrenocorticotropic hormone (ACTH) or oral steroids, and vigabatrin, particularly effective in cases associated with tuberous sclerosis. When considering treatment in special populations, such as pregnant or lactating women with epilepsy, it is imperative to balance the benefits of seizure control with the potential risks to the fetus or nursing infant. Current guidelines stress careful evaluation and use of the safest therapeutic options, along with close monitoring. Option A, which identifies hypsarrhythmia on EEG, is the correct choice as it directly correlates with the pathognomonic findings in West syndrome. Options B (generalized spike-wave discharges), C (focal epileptiform discharges), and D (slow spike-and-wave pattern) are more typical of absence epilepsy, focal epilepsies, and Lennox-Gastaut syndrome respectively, and hence do not match the clinical scenario presented. Early recognition and management of West syndrome can be crucial in improving long-term neurological outcomes. The presence of a chaotic, high-amplitude EEG (hypsarrhythmia) in an infant with spasms and developmental delay is a red flag that demands prompt intervention. Recent research supports the early initiation of ACTH or vigabatrin to potentially improve developmental outcomes in West syndrome. Ongoing studies are focused on understanding the genetic etiologies and refining treatment protocols, with a strong emphasis on tailoring therapy to minimize adverse effects, especially in sensitive populations such as pregnant or lactating patients.",
    "exam_year": "2024",
    "exam_type": "Part II",
    "image_url": "page_3.png"
  }
]